<?xml version="1.0" encoding="UTF-8"?>
<p>To demonstrate the safety and efficacy of plant-derived NoV VLPs, a Phase I clinical trial was conducted with potato-produced NVCP VLPs. In this trial, two or three doses of 150 g uncooked NVCP-transgenic potato tubers (215–751 μg VLPs per dose) were orally ingested by 20 human subjects on days 0 and 7, or on days 0, 7, and 21 [
 <xref ref-type="bibr" rid="CR0008149">149</xref>].
</p>
